Inactivation of the p16 tumor suppressor gene in adrenocortical tumors

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 8, 1999, Pages 2776-2779

  Pilon, Catia ^a   Pistorello, Matteo ^a   Moscon, Alessandro ^a   Altavilla, Giuseppe ^a   Pagotto, Uberto ^a   Boscaro, Marco ^a   Fallo, Francesco ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b Department of Medical and Surgical Sciences   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16;

ADRENAL CORTEX TUMOR; ADULT; AGED; ARTICLE; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CHROMOSOME 9P; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE INACTIVATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE;

EID: 0033308652     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.84.8.2776     Document Type: Article

References (34)

1. Adrenocortical tumors
2. Neoplasms of the adrenal cortex
3. Adrenocortical carcinoma: Experience in 45 cases
4. Recent advances in the pathogenesis of adrenocortical tumors
5. Clonal composition of human adrenocortical neoplasm
6. Clonal analysis of human adrenocortical carcinomas and secreting adenomas
7. Mutations in adrenocortical tumors
8. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors
9. Mutations of the p53 gene in human functional adrenal neoplasms
10. p53 Mutations in human adrenocortical neoplasms: Immunohistochemical and molecular studies
11. Molecular genetic studies on adrenal tumors
12. Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small cell lung cancers
13. Frequent loss on chromosome 9p21-22 early in head and neck cancer progression
14. Frequency of deletion of p16/CDKN2 in primary human tumours
15. Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: The deleted region involves markers outside of the MTS1 and MTS2 genes
16. Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas
17. Unrestricted cell cycling and cancer
18. A cell cycle regulator potentially involved in genesis of many tumor types
19. Cyclin and cancer II: Cyclin D and cdk inhibitors come of age
20. Cell-cycle regulators and cancer
21. The Cushing's syndrome: An update on diagnostic tests
22. Primary aldosteronism
23. Incidentally discovered adrenal tumors: Endocrine and scintigrafic correlates
24. Pathologic features of prognostic significance in adrenocortical carcinoma
25. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures
26. Genomic structure, expression and mutational analysis of the P15 (MTS2) gene
27. p15(INK4B) is a potential effector of TGF-β-induced cell cycle arrest
28. High frequency of p16 (CDNK2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma
29. Immunohistochemical analysis of the p16(INK4A) cyclin-dependent kinase inhibitor in malignant mesothelioma
30. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (cdkn2/mts1) product p16(INK4) in archival human solid tumors: Correlation with retinoblastoma protein expression
31. Risk factors and long-term follow-up of adrenal incidentalomas